Drugs / GVAX vaccine
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04239040 | Jan 2020 → Jan 2024 | childhood neoplasm, neuroblastoma | Dana-Farber Cancer Institute | Terminated | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | GVAX vaccine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04239040 ↗ |
| Modality | Vaccine | “GVAX, an irradiated GM-CSF secreting, autologous neuroblastoma cell vaccine (GVAX)” NCT04239040 ↗ |